Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors associated with dose reduction…
In both clinical and experimental trials, pirfenidone (PFD) showed anti-inflammatory and antifibrogenic effects. Considering the wide variation in hepatic functional reserve in patients with cirrhosis, we decided to learn more about the pharmacokinetics of a new formulation of prolonged release PFD in this population (PR-PFD), focusing on assessing changes on AUC0–∞, AUC0–t, and Cmax.
Although pirfenidone slows disease progression in patients with idiopathic pulmonary fibrosis (IPF), in clinical practice, patients often cannot tolerate the recommended dose because of several adverse events. This study aimed to investigate adverse events associated with pirfenidone and factors associated with dose reduction…
La neumonitis por hipersensibilidad (NH) es una forma inmunológicamente mediada de enfermedad pulmonar, resultante de la exposición por inhalación a una gran variedad de antígenos. En los Estados Unidos, la prevalencia anual estimada de NH oscila entre 1.67 y 2.71 casos por cada 100 000 personas. Entre el 56% y el 68% de los casos de NH cada año se consideran enfermedad crónica y entre los casos crónicos, aproximadamente el 36%-48% tienen una presentación con fibrosis pulmonar. Una gran proporción de pacientes con Neumonitis fibrótica por hipersensibilidad (NFH) desarrollan progresión sintomática, funcional y radiográfica de la enfermedad.
Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients’ reported symptoms and expectations of the therapy.
